AUGMENTA BIOWORKS, INC.

Biotech · Private

Fluorescently-activatable CAR-T reporter cell line platform (PANACEA) for high-throughput discovery and screening of novel CAR-T receptors and their ligands

Grants
$222K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
22
3 granted · 19 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Fluorescent Chimeric Antigen Receptor T Cell (CAR-T) Reporter Assay$221,719
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1208Kodiak Sciences Inc.—$36M
1209MIRNATECH INTERNATIONAL, INC.——
1210VIVASC THERAPEUTICS INC——
1211AUGMENTA BIOWORKS, INC.——
1212Dianomi Therapeutics, Inc.—$185K
1213Novoglia, Inc.—$37M
1214Matrubials, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 3 granted of 22
  • Antibodies For SARS-COV-2 And Uses Thereofapplication
  • Antibodies For SARS-COV-2 And Uses Thereofgranted
  • Methods for Isolating Immune Binding Proteinsapplication
  • Methods for Isolating Immune Binding Proteinsgranted
  • Methods for Making Gel Beads and Core and Shell Beads with a Cellapplication
  • Immune Repertoire Sequence Amplification Methods and Applicationsapplication
  • Immune Repertoire Sequence Amplification Methods and Applicationsgranted
  • Isolation of Single Cells and Uses Thereofapplication
  • Methods for Making Gel Beads and Core and Shell Beads with a Cellapplication
  • Antibodies For SARS-COV-2 And Uses Thereofapplication
  • Isolation Of Single Cells And Uses Thereofapplication
  • Antibodies For SARS-COV-2 And Usesthereofapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.